Heart shield for chemo: new study tests carvedilol in breast cancer patients
NCT ID NCT04023110
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 29 times
Summary
This early-phase study tested whether giving the heart medication carvedilol to breast cancer patients at high risk for heart problems could safely protect their hearts during chemotherapy with doxorubicin and/or trastuzumab. 68 women with stage I-III breast cancer participated. The goal was to see if this risk-guided approach was safe, tolerable, and practical, not to prove it prevents heart failure. Results focus on heart function and medication adherence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.